Janney Montgomery Scott assumed coverage on shares of Uniqure (NASDAQ:QURE) in a research note issued to investors on Wednesday, January 3rd, MarketBeat Ratings reports. The firm set a “buy” rating and a $25.00 price target on the biotechnology company’s stock. Janney Montgomery Scott’s target price points to a potential upside of 33.19% from the company’s previous close.

A number of other research firms have also recently weighed in on QURE. HC Wainwright set a $28.00 price target on shares of Uniqure and gave the company a “buy” rating in a report on Thursday, December 7th. BidaskClub raised shares of Uniqure from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Leerink Swann raised their price target on shares of Uniqure from $19.00 to $26.00 in a research report on Tuesday, November 7th. Zacks Investment Research raised shares of Uniqure from a “sell” rating to a “hold” rating and set a $21.00 price target for the company in a research report on Tuesday, October 24th. Finally, Oppenheimer reissued a “hold” rating on shares of Uniqure in a research report on Friday, November 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $20.00.

Uniqure (QURE) opened at $18.77 on Wednesday. Uniqure has a 1-year low of $4.72 and a 1-year high of $21.35. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.64 and a quick ratio of 3.64.

Uniqure (NASDAQ:QURE) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.25. Uniqure had a negative net margin of 338.39% and a negative return on equity of 170.28%. equities analysts forecast that Uniqure will post -2.97 earnings per share for the current year.

In related news, insider Christian Klemt sold 5,093 shares of Uniqure stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $20.13, for a total value of $102,522.09. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Matthew C. Kapusta sold 21,690 shares of Uniqure stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $19.87, for a total transaction of $430,980.30. The disclosure for this sale can be found here. Insiders sold a total of 32,647 shares of company stock worth $651,545 in the last three months. 0.73% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in QURE. SG Americas Securities LLC acquired a new stake in Uniqure during the 4th quarter worth $119,000. Mangrove Partners acquired a new stake in Uniqure during the 2nd quarter worth $247,000. JPMorgan Chase & Co. boosted its stake in Uniqure by 33.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock worth $362,000 after purchasing an additional 14,659 shares during the last quarter. OxFORD Asset Management LLP acquired a new stake in Uniqure during the 3rd quarter worth $399,000. Finally, First Manhattan Co. acquired a new stake in Uniqure during the 4th quarter worth $1,371,000. 24.95% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.mareainformativa.com/2018/01/30/uniqure-qure-earns-buy-rating-from-analysts-at-janney-montgomery-scott-updated-updated-updated.html.

Uniqure Company Profile

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.